K. Bélanger - Concepedia

Author

K. Bélanger

Université de Montréal

Also Known As

K Belanger, K. Belanger, K. Bélanger, KAITLYN BELANGER, Kayla Belanger

Publications

659

Citations

H-Index

Concepts

All Affiliations

Université de Montréal Ottawa Regional Cancer Foundation Hôpital Notre-Dame

About

K. Bélanger is an author at Université de Montréal specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	257
2	Health Sciences	3	3	162
3	Neurology	2	2	130
4	Immunology	1	1	23
5	Molecular Medicine	1	1	23

K. Bélanger

Publications

609

Citations

H-Index

Page 1

	Year	Citations
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma Michael Weller, Thierry Gorlia, J. G. Cairncross, Neurology	2011	291
Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme Jacob C. Easaw, Warren Mason, James Perry, Current Oncology Surgical OncologyOncologic ImagingCancer ManagementMultimodalitySurgery	2011	105
Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115 J. Maroun, K. Bélanger, Lesley Seymour, Annals of Oncology National Cancer InstituteSolid TumorsMedicineCancer ManagementPharmacology	2006	70
Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials Group Carol Townsley, K. Chi, D. Scott Ernst, Journal of Clinical Oncology	2003	37
NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94) S. Gertler, David Macdonald, Michael Goodyear, Annals of Oncology GliomaMedicineMetronomic TherapyMalignant GliomaHigh-grade Gliomas	2000	34
The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma James Perry, Warren Mason, K. Bélanger, Journal of Clinical Oncology Dose-intense TemozolomideTemozolomide Rescue StudyHigh-grade GliomasDay TmzGlioma	2008	25
Procarbazine, Lomustine and Vincristine Toxicity in Low-Grade Gliomas Gabrielle Jutras, K. Bélanger, Nathalie Letarte, Current Oncology	2018	24
Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a phase I and clinical pharmacological study. P A Speth, Timothy J. Kinsella, K. Bélanger, PubMed ImmunologyIdurd IncorporationFluorodeoxyuridine ModulationRadiation MedicineHematology	1988	23

Page 1